• Atopic dermatitis

Adbry Generic Name & Formulations

General Description

Tralokinumab-ldrm 150mg/mL; soln for SC inj; preservative-free.

Pharmacological Class

Interleukin-13 (IL-13) antagonist.

How Supplied

Single-dose prefilled syringe (w. needle guard)—2, 4


Generic Availability


Adbry Indications


Moderate to severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. May be used with or without topical corticosteroids.

Adbry Dosage and Administration


Give by SC inj into the thigh or abdomen (except for 2 inches around the navel); upper arm may be used if caregiver administers inj. Rotate inj sites. Initially 600mg (four 150mg inj), followed by 300mg (two 150mg inj) every other week. After 16 weeks, may consider 300mg every 4 weeks for patients weighing <100kg who achieve clear or almost clear skin. Concomitant topical calcineurin inhibitors: reserve for problem areas only (eg, face, neck, intertriginous, genital areas).


Not established.

Adbry Contraindications

Not Applicable

Adbry Boxed Warnings

Not Applicable

Adbry Warnings/Precautions


Discontinue immediately if serious hypersensitivity reactions occur. New onset or worsening eye symptoms. Helminth infections: treat pre-existing infections prior to initiation; discontinue Adbry if become infected during therapy until infection resolves. Complete all vaccinations according to current guidelines prior to initiation. Pregnancy. Nursing mothers.

Adbry Pharmacokinetics

See Literature

Adbry Interactions


Avoid concomitant live vaccines.

Adbry Adverse Reactions

Adverse Reactions

Upper respiratory tract infections, conjunctivitis, inj site reactions, eosinophilia; anaphylaxis, angioedema, keratitis.

Adbry Clinical Trials

See Literature

Adbry Note

Not Applicable

Adbry Patient Counseling

See Literature